| IMMURON LTD |
| Australien |
| Gesundheit |
| AU000000IMC7 / A0RDPK |
| ANW (Frankfurt) |
| FRA:ANW, ETR:ANW, ANW:GR |
| - |
| https://www.immuron.com.a.. |
|
Immuron Limited is an Australian biopharmaceutical company specializing in the development and commercialization of orally delivered targeted polyclonal antibodies, with a primary focus on treating infectious and inflammatory diseases of the gastroin..
>Volltext.. |
| 5.42 Mio. EUR |
| -0.5 Mio. EUR |
| 4.31 Mio. EUR |
| - |
| -2.68 Mio. EUR |
| -0.01 EUR |
| - |
| 5.77 Mio. EUR |
| -2.62 Mio. EUR |
| 5.39 |
| 14.3% |
| 36.81% |
| - |
| - |
| - |
| - |
| IMMURON |
| 02.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|